Good news, glad to see this move onto the TGAs special access...

Good news, glad to see this move onto the TGAs special access scheme too

Key Highlights:
• The Phase II clinical trial, which commences today, is to evaluate the potential behavioural
benefits CogniCann® may have on patients with dementia and Alzheimer’s disease
• The Trial will involve a total of 50 patients, aged 65 and older, from various aged care facilities
in Perth, Western Australia
• New patients are expected to commence treatment each week, with the Trial lasting 18
weeks per patient
• Results of the trial are conservatively expected by the end of Q3 2021
• The Trial is looking to confirm the clinical efficacy of the drug (CogniCann®) and determine
the therapeutic individual dose response
• The Trial is a randomised double blind, crossover, placebo-controlled clinical trial
• CogniCann® is also now available for prescription in Australia under the Special Access
Scheme through the Company's distributors, Health House International and Cannvalate
• It is estimated that nearly 500,000 people in Australia suffer from Alzheimer’s disease, with
approximately 80% having mild or moderate symptoms1
. In Europe, this number is closer to
1.5 million and is expected to grow by 15% by 20242
•CogniCann® is currently the only dementia targeting phytocannabinoid-derived product
available for prescription in Australia, putting the Company in a unique position to access a
large patient population in Australia and key international markets via early access schemes